Journal
SUPPORTIVE CARE IN CANCER
Volume 30, Issue 11, Pages 9307-9315Publisher
SPRINGER
DOI: 10.1007/s00520-022-07339-1
Keywords
Chemotherapy-induced nausea and vomiting; Cost-effectiveness; Antiemetics; Netupitant; Palonosetron; NEPA
Funding
- Helsinn Healthcare SA
Ask authors/readers for more resources
This study assessed the cost-effectiveness of NEPA in the Spanish market and compared it to other available treatments. The results showed that NEPA is more effective and less costly compared to other treatments.
Purpose The aim of this study was to assess the cost-effectiveness of NEPA, a fixed-dose combination of oral netupitant (300 mg) and palonosetron (0.5 mg), compared to available treatments in Spain after aprepitant generic introduction in the market, and to discuss results in previously performed analyses in different wordwide settings. Methods A Markov model including three health states, complete protection, complete response at best and incomplete response, was used to evaluate the cost-effectiveness of NEPA versus common treatment options in Spain during 5 days after chemotherapy. Incremental costs including treatment costs and treatment failure management cost as well as incremental effects including quality adjusted life days (QALDs) and emesis-free days were compared between NEPA and the comparator arms. The primary outcomes were cost per avoided emetic event and cost per QALDs gained. Results NEPA was dominant (more effective and less costly) against aprepitant combined with palonosetron, and fosaprepitant combined with granisetron, while, compared to generic aprepitant plus ondansetron, NEPA showed an incremental cost per avoided emetic event of euro33 and cost per QALD gained of euro125. Conclusion By most evaluations, NEPA is a dominant or cost-effective treatment alternative to current antiemetic standards of care in Spain during the first 5 days of chemotherapy treatment in cancer patients, despite the introduction of generics. These results are in line with previously reported analyses throughout different international settings.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available